个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Song, Yuqin[1] ; Li, Zengjun[2] ; Wu, Huijing[3] ; Jin, Jie[4] ; Zhou, Hui[5] ; Zhou, Keshu[6] ; Zhang, Liling[7] ; Peng, Zhigang[8] ; Zhang, Zhiye[9] ; Cen, Hong[10] ; Jia, Youchao[11] ; Shuang, Yuerong[12] ; Li, Zhiming[13] ; Yang, Haiyan[14] ; Zou, Liqun[15] ; Li, Zhifeng[16,17] ; Zhang, Zhihui[18] ; Li, Junmin[19] ; Cao, Junning[20] ; Qiu, Lugui[21] ; Wu, Shaojie[22] ; Gong, Tiejun[23] ; Xu, Xiaohong[24] ; Wang, Zhen[25] ; Zhu, Jun[26] ;
机构： [1]Peking Univ, Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China [3]Hubei Canc Hosp, Wuhan, Peoples R China [4]Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China [5]Hunan Canc Hosp, Changsha, Peoples R China [6]Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China [7]Huazhong Univ Sci & Technol, Canc Ctr, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China [8]Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Naning, Peoples R China [9]Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Oncol, Luoyang, Peoples R China [10]Guangxi Med Univ, Affiliated Tumor Hosp, Dept Med Oncol, Nanning, Peoples R China [11]Hebei Univ, Dept Med Oncol, Affiliated Hosp, Baoding, Peoples R China [12]Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China [13]Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China [14]Zhejiang Canc Hosp, Hangzhou, Peoples R China [15]Sichuan Univ, Dept Med Oncol, West China Sch Med, West China Hosp, Chengdu, Peoples R China [16]Xiamen Univ, Affiliated Hosp 1, Dept Hematol, Xiamen, Peoples R China [17]Xiamen Univ, Sch Med, Inst Hematol, Xiamen, Peoples R China [18]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [19]Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China [20]Fudan Univ, Shanghai Canc Ctr, Dept Lymphoma, Shanghai, Peoples R China [21]Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst,Inst Hematol & Blood Dis H, Tianjin, Peoples R China [22]Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Peoples R China [23]Harbin First Hosp, Inst Hematol & Oncol, Harbin, Peoples R China [24]Nantong Univ, Dept Hematol & Lymphoma, Canc Hosp, Nantong, Peoples R China [25]Linyi Canc Hosp, Linyi, Shandong, Peoples R China [26]Peking Univ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst,Minist Educ, Beijing, Peoples R China
出处：
DOI： 10.1182/blood-2023-180137
ISSN：

摘要：
Introduction Peripheral T/NK cell lymphomas (PTCLs) are a group of aggressive heterogeneous non-Hodgkin’s lymphomas where in relapsed or refractory (r/r) disease, the approved standard therapies are limited with a median progression free survival (mPFS) of only 3-4 months. PI3Kdelta inhibitors have demonstrated clinical activities in T-cell and B-cell lymphomas, owing to the multiple cellular activities in the T, B, and myeloid cell tumor microenvironment.

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 血液学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 血液学
JCR分区：
出版当年[2023]版：
Q1 HEMATOLOGY
最新[2023]版：
Q1 HEMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Peking Univ, Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Song Yuqin,Li Zengjun,Wu Huijing,et al.A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas[J].BLOOD.2023,142:doi:10.1182/blood-2023-180137.
APA：
Song, Yuqin,Li, Zengjun,Wu, Huijing,Jin, Jie,Zhou, Hui...&Zhu, Jun.(2023).A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas.BLOOD,142,
MLA：
Song, Yuqin,et al."A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas".BLOOD 142.(2023)

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号